Korea FDA Approves GSK’s Synflorix Vaccine For Children Older Than 5
This article was originally published in PharmAsia News
Executive Summary
South Korea drug authorities granted GlaxoSmithKline an additional indication for its Synflorix pneumonia vaccine, allowing the firm to promote it for use in children up to 5 years of age.